Baseline Laboratory Tests Before Starting Depakote
Before initiating Depakote (valproic acid), you must obtain: complete blood count (CBC) with platelets, comprehensive metabolic panel including liver function tests (AST, ALT, bilirubin), and a pregnancy test in all females of childbearing potential. 1
Essential Pre-Treatment Laboratory Panel
The FDA drug label and clinical guidelines establish the following mandatory baseline tests 2, 1:
Hematologic Studies
- Complete blood count with differential and platelet count - Valproate causes dose-related thrombocytopenia in approximately 27% of patients, with risk increasing significantly at levels ≥110 mcg/mL (females) or ≥135 mcg/mL (males) 1
- Coagulation parameters (PT/INR, PTT) - Valproate inhibits secondary platelet aggregation and can cause coagulation factor deficiencies and acquired von Willebrand's disease 1
Hepatic Function
- Liver function tests (AST, ALT, bilirubin, alkaline phosphatase) - Fatal hepatotoxicity occurs most commonly in the first 6 months of therapy, particularly in children under 2 years 1. Serum liver tests must be performed before therapy initiation 1
- These tests are critical because hepatic failure can occur even with normal initial values, requiring close monitoring 1
Renal and Metabolic Studies
For patients with epilepsy (per guideline recommendations) 2:
- Blood urea nitrogen (BUN) and creatinine
- Serum calcium
- Urinalysis
Reproductive Health
- Pregnancy test in all females of childbearing potential - This is mandatory given valproate's teratogenicity and contraindication for migraine prophylaxis in pregnant women or those not using effective contraception 2, 1
Additional Baseline Considerations
Ammonia Level
While not universally required at baseline, consider obtaining an ammonia level in patients with:
- History of unexplained encephalopathy
- Suspected mitochondrial disorders
- Concomitant topiramate use planned 1
Genetic Testing Considerations
POLG mutation testing should be performed before starting valproate in 1:
- Children under 2 years with suspected mitochondrial disease
- Patients with family history of POLG-related disorders
- Those with unexplained encephalopathy, refractory epilepsy, developmental delays, or psychomotor regression
Valproate is absolutely contraindicated in known POLG mutations 1.
Critical Pitfalls to Avoid
Do not skip the pregnancy test - Valproate is contraindicated for migraine prophylaxis in pregnancy and requires effective contraception 1
Do not rely solely on liver enzymes - Fatal hepatotoxicity can occur despite normal biochemistry; clinical monitoring for malaise, weakness, lethargy, facial edema, anorexia, and vomiting is equally important 1
Children under 2 years require extreme caution - This population has considerably increased risk of fatal hepatotoxicity and should only receive valproate as monotherapy after careful risk-benefit assessment 1
Document baseline values meticulously - You need these for comparison during the critical first 6 months when most serious adverse events occur 1
Monitoring Framework After Baseline
Once baseline labs are obtained and valproate is initiated, repeat CBC, liver function tests, and coagulation parameters every 3-6 months, with more frequent monitoring during the first 6 months 2. However, clinical vigilance for symptoms of hepatotoxicity or bleeding complications must be continuous, as periodic lab monitoring does not guarantee early detection of all abnormalities 2, 1.